AlphaCentric Advisors’s Gilead Sciences GILD Stock Holding History

AlphaCentric Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.58M	Buy	20,426 +166	+0.8%	+$21.9K	2.19%	1
2026 Q1	$2.82M	Sell	20,260 -1,501	-7%	-$210K	2.82%	1
2025 Q4	$2.67M	Buy	+21,761	New	+$2.64M	2.66%	1
2024 Q4	$976K	Buy	10,562 +7,062	+202%	+$636K	0.97%	30
2024 Q3	$293K	Hold	3,500	–	–	0.22%	110
2024 Q2	$240K	Hold	3,500	–	–	0.18%	107
2024 Q1	$256K	Sell	3,500 -5,000	-59%	-$384K	0.15%	112
2023 Q4	$689K	Hold	8,500	–	–	0.46%	63
2023 Q3	$637K	Hold	8,500	–	–	0.36%	83
2023 Q2	$655K	Hold	8,500	–	–	0.36%	84
2023 Q1	$705K	Hold	8,500	–	–	0.49%	73
2022 Q4	$730K	Sell	8,500 -5,000	-37%	-$396K	0.72%	52
2022 Q3	$833K	Buy	+13,500	New	+$851K	0.85%	38
2021 Q4	–	Sell	-11,500	Closed	-$803K	–	242
2021 Q3	$803K	Sell	11,500 -300	-3%	-$21.1K	0.2%	42
2021 Q2	$813K	Hold	11,800	–	–	0.22%	35
2021 Q1	$763K	Hold	11,800	–	–	0.26%	32
2020 Q4	$687K	Buy	11,800 +9,650	+449%	+$582K	0.29%	21
2020 Q3	$136K	Buy	2,150 +1,500	+231%	+$104K	0.07%	59
2020 Q2	$50K	Buy	+650	New	+$49.8K	0.03%	86

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCentric Advisors's GILD Position: Q2 2026 in Review

AlphaCentric Advisors increased its Gilead Sciences (GILD) stake by 0.82% in Q2 2026, buying an estimated $21.9K and bringing the position to 20,426 shares worth $2.58M. The position accounts for 2.19% of the portfolio, ranked #1.

AlphaCentric Advisors first reported a position in GILD in Q2 2020 and has held it in 19 quarters since. The position peaked at $2.82M in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

AlphaCentric Advisors held 20,426 shares of Gilead Sciences worth $2.58M as of Q2 2026.
AlphaCentric Advisors bought 166 Gilead Sciences shares in Q2 2026, an estimated $21.9K.
Gilead Sciences made up 2.19% of AlphaCentric Advisors's portfolio in Q2 2026, its #1 holding.
AlphaCentric Advisors first reported a position in Gilead Sciences in Q2 2020 and has held it in 19 quarters since.
AlphaCentric Advisors's Gilead Sciences position peaked at $2.82M in Q1 2026.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.